Novo Nordisk has filed a lawsuit against rival Eli Lilly (LLY), accusing the US drugmaker of running “false and misleading” advertisements for its obesity drug Zepbound.
The legal clash between two of the world’s biggest pharmaceutical companies marks a significant escalation in the fiercely competitive obesity drug market, where billions of dollars are at stake.
Novo Nordisk (NVO), the Danish company behind the rival GLP-1 treatment Wegovy, is seeking to challenge what it describes as deceptive marketing practices by its American competitor.
Beyond the courtroom battle over GLP-1 weight-loss drugs, the broader biopharma industry is also watching developments in the emerging field of psychedelic medicines with growing interest.
Eli Lilly’s (LLY) move into psychedelics has prompted industry analysts and observers to ask whether other major pharmaceutical companies will follow the same path into this once-fringe area of medicine.
Reports suggest a “rising tide scenario” could be unfolding, where further acquisitions in the psychedelics space prompt a wave of similar dealmaking among Big Pharma rivals looking to diversify their pipelines.
Separately, a closely watched US Food and Drug Administration advisory committee meeting on peptides has drawn significant attention, partly due to political controversy surrounding the proceedings.
On the first day of the adcomm, peptides received a broadly favourable reception from panel members, signalling potential regulatory momentum for this category of compounds.
However, the second day of the advisory committee meeting produced a notable setback, as the peptide compound emideltide was voted down in the panel’s first significant pushback of the session.
Peptides have attracted growing public curiosity in recent months, with many consumers and investors asking basic questions about what these compounds are and how they differ from other drug classes.
The combination of psychedelic acquisitions, regulatory decisions on peptides, and a high-profile legal battle between Novo Nordisk and Eli Lilly reflects a biopharma landscape undergoing rapid and sometimes turbulent change in 2026.
Taken together, these developments signal a period of heightened competition, scientific ambition, and regulatory scrutiny that is reshaping how the global pharmaceutical industry operates and invests.